Literature DB >> 30612307

Cinnamic Acid Protects the Nigrostriatum in a Mouse Model of Parkinson's Disease via Peroxisome Proliferator-Activated Receptorα.

Tim Prorok1,2, Malabendu Jana1,2, Dhruv Patel1,2, Kalipada Pahan3,4.   

Abstract

Parkinson's disease (PD) is the second most common devastating human neurodegenerative disorder and despite intense investigation, no effective therapy is available for PD. Cinnamic acid, a naturally occurring aromatic fatty acid of low toxicity, is a precursor for the synthesis of a huge number of plant substances. This study highlights the neuroprotective effect of cinnamic acid in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD. Oral administration of cinnamic acid protected tyrosine hydroxylase (TH)-positive dopaminergic neurons in the substantia nigra pars compacta (SNpc) and TH fibers in the striatum of MPTP-insulted mice. Accordingly, oral cinnamic acid also normalized striatal neurotransmitters and improved locomotor activities in MPTP-intoxicated mice. While investigating mechanisms, we found that cinnamic acid induced the activation of peroxisome proliferator-activated receptor α (PPARα), but not PPARβ, in primary mouse astrocytes. Cinnamic acid mediated protection of the nigrostriatal system and locomotor activities in WT and PPARβ (-/-), but not PPARα (-/-) mice from MPTP intoxication suggests that cinnamic acid requires the involvement of PPARα in protecting dopaminergic neurons in this model of PD. This study delineates a new function of cinnamic acid in protecting dopaminergic neurons via PPARα that could be beneficial for PD.

Entities:  

Keywords:  Dopamine; MPTP; PPARα; Parkinson’s disease; Tyrosine hydroxylase

Mesh:

Substances:

Year:  2019        PMID: 30612307      PMCID: PMC6450560          DOI: 10.1007/s11064-018-02705-0

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  54 in total

Review 1.  Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease.

Authors:  Douglas L Feinstein
Journal:  Diabetes Technol Ther       Date:  2003       Impact factor: 6.118

2.  Protocol for the MPTP mouse model of Parkinson's disease.

Authors:  Vernice Jackson-Lewis; Serge Przedborski
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

3.  The dependence of serum interleukin-6 level on PPAR-alpha polymorphism in men with coronary atherosclerosis.

Authors:  Anna Skoczynska; Tadeusz Dobosz; Rafal Poreba; Barbara Turczyn; Arkadiusz Derkacz; Magdalena Zoledziewska; Anna Jonkisz; Arleta Lebioda
Journal:  Eur J Intern Med       Date:  2005-11       Impact factor: 4.487

4.  A population-based case-control study of farming and breast cancer in North Carolina.

Authors:  E J Duell; R C Millikan; D A Savitz; B Newman; J C Smith; M J Schell; D P Sandler
Journal:  Epidemiology       Date:  2000-09       Impact factor: 4.822

Review 5.  Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.

Authors:  S Fahn
Journal:  Arch Neurol       Date:  1999-05

Review 6.  Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms.

Authors:  Daniel S Straus; Christopher K Glass
Journal:  Trends Immunol       Date:  2007-11-05       Impact factor: 16.687

7.  Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes.

Authors:  Kalipada Pahan; Malabendu Jana; Xiaojuan Liu; Bradley S Taylor; Charles Wood; Susan M Fischer
Journal:  J Biol Chem       Date:  2002-09-18       Impact factor: 5.157

8.  PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats.

Authors:  Tetsuya Toyama; Hideki Nakamura; Yuichi Harano; Norihito Yamauchi; Atsuhiro Morita; Toshihiko Kirishima; Masahito Minami; Yoshito Itoh; Takeshi Okanoue
Journal:  Biochem Biophys Res Commun       Date:  2004-11-12       Impact factor: 3.575

9.  Peroxisome proliferator-activated receptor-alpha is required for the neurotrophic effect of oleic acid in neurons.

Authors:  André Bento-Abreu; Arantxa Tabernero; José M Medina
Journal:  J Neurochem       Date:  2007-08-07       Impact factor: 5.372

10.  Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation.

Authors:  Thomas Dehmer; Michael T Heneka; Magdalena Sastre; Johannes Dichgans; Jörg B Schulz
Journal:  J Neurochem       Date:  2004-01       Impact factor: 5.372

View more
  7 in total

1.  Gemfibrozil Protects Dopaminergic Neurons in a Mouse Model of Parkinson's Disease via PPARα-Dependent Astrocytic GDNF Pathway.

Authors:  Carl G Gottschalk; Malabendu Jana; Avik Roy; Dhruv R Patel; Kalipada Pahan
Journal:  J Neurosci       Date:  2021-01-29       Impact factor: 6.167

Review 2.  Natural product-based radiopharmaceuticals: Focus on curcumin and its analogs, flavonoids, and marine peptides.

Authors:  Hendris Wongso
Journal:  J Pharm Anal       Date:  2021-07-21

Review 3.  Potential Therapeutic Benefits of Honey in Neurological Disorders: The Role of Polyphenols.

Authors:  Arslan Iftikhar; Rimsha Nausheen; Humaira Muzaffar; Muhammad Ahsan Naeem; Muhammad Farooq; Mohsin Khurshid; Ahmad Almatroudi; Faris Alrumaihi; Khaled S Allemailem; Haseeb Anwar
Journal:  Molecules       Date:  2022-05-20       Impact factor: 4.927

Review 4.  Natural Antioxidant Compounds as Potential Pharmaceutical Tools against Neurodegenerative Diseases.

Authors:  Attilio Marino; Matteo Battaglini; Nadia Moles; Gianni Ciofani
Journal:  ACS Omega       Date:  2022-07-19

Review 5.  Impact of Phytochemicals on PPAR Receptors: Implications for Disease Treatments.

Authors:  Ayesheh Enayati; Mobina Ghojoghnejad; Basil D Roufogalis; Seyed Adel Maollem; Amirhossein Sahebkar
Journal:  PPAR Res       Date:  2022-08-31       Impact factor: 4.385

6.  Cinnamic acid ameliorate gentamicin-induced liver dysfunctions and nephrotoxicity in rats through induction of antioxidant activities.

Authors:  Esmaeel Babaeenezhad; Negar Nouryazdan; Maryam Nasri; Hassan Ahmadvand; Mostafa Moradi Sarabi
Journal:  Heliyon       Date:  2021-07-02

7.  Propolis as A Potential Disease-Modifying Strategy in Parkinson's Disease: Cardioprotective and Neuroprotective Effects in the 6-OHDA Rat Model.

Authors:  Valeria C Gonçalves; Daniel J L L Pinheiro; Tomás de la Rosa; Antônio-Carlos G de Almeida; Fúlvio A Scorza; Carla A Scorza
Journal:  Nutrients       Date:  2020-05-26       Impact factor: 5.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.